REGENERON PHARMACEUTICALS, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2019-09-30 was $8.30M, a 85.51% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2019-06-30 was $13.90M, a 29.80% decline year-over-year.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2019-03-31 was $140.90M, a 936.03% increase year-over-year.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for the quarter ending 2018-09-30 was $57.30M.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2018 was $114.20M, a 52.54% decline from fiscal 2017.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2017 was $240.60M, a 108.85% increase from fiscal 2016.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2016 was $115.20M, a 46.53% decline from fiscal 2015.
- REGENERON PHARMACEUTICALS, INC. stock issued during period, value, stock options exercised for fiscal 2015 was $215.46M, a 71.14% increase from fiscal 2014.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2019-09-30 | $8.30M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $13.90M 10-Q · filed 2019-11-05 | |
| 2019-03-31 | $140.90M 10-Q · filed 2019-11-05 | |
| 2018-12-31 | $114.20M 10-K · filed 2019-02-07 | |
| 2018-09-30 | $57.30M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $19.80M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $13.60M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $240.60M 10-K · filed 2019-02-07 | |
| 2016-12-31 | $115.20M 10-K · filed 2019-02-07 | |
| 2015-12-31 | $215.46M 10-K · filed 2018-02-08 | |
| 2014-12-31 | $46.20M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-09 | $125.90M 10-K · filed 2017-02-09 |
| 2014-09-30 | $17.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $91.83M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-06-30 | $8.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $86.38M derived: sum of 4 quarters · filed 2016-02-11 |
| 2014-03-31 | $53.92M 10-Q · filed 2014-05-08 | $98.88M derived: sum of 4 quarters · filed 2016-02-11 |
| 2013-12-31 | $12.14M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-11 | $54.76M 10-K · filed 2016-02-11 |
| 2013-09-30 | $12.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $61.36M derived: sum of 4 quarters · filed 2015-02-12 |
| 2013-06-30 | $20.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $58.04M derived: sum of 4 quarters · filed 2015-02-12 |
| 2013-03-31 | $9.80M 10-Q · filed 2014-05-08 | $45.23M derived: sum of 4 quarters · filed 2015-02-12 |
| 2012-12-31 | $18.73M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-12 | $67.17M 10-K · filed 2015-02-12 |
| 2012-09-30 | $8.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $51.92M derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-06-30 | $7.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $54.75M derived: sum of 4 quarters · filed 2014-02-13 |
| 2012-03-31 | $31.75M 10-Q · filed 2013-05-03 | $60.26M derived: sum of 4 quarters · filed 2014-02-13 |
| 2011-12-31 | $3.48M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-13 | $43.62M 10-K · filed 2014-02-13 |
| 2011-09-30 | $11.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-24 | $52.21M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-06-30 | $13.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25 | $42.37M derived: sum of 4 quarters · filed 2013-02-15 |
| 2011-03-31 | $15.10M 10-Q · filed 2011-05-03 | $31.71M derived: sum of 4 quarters · filed 2013-02-15 |
| 2010-12-31 | $12.07M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-15 | $25.26M 10-K · filed 2013-02-15 |
| 2010-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27 | $17.84M derived: sum of 4 quarters · filed 2011-10-27 |
| 2010-06-30 | $2.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28 | $18.96M derived: sum of 4 quarters · filed 2011-07-28 |
| 2010-03-31 | $8.66M 10-Q · filed 2011-05-03 | |
| 2009-12-31 | $4.64M derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-17 | $9.27M 10-K · filed 2011-02-17 |
| 2009-09-30 | $2.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-28 | |
| 2008-12-31 | $7.95M 10-K · filed 2011-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |